Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Tallac’s pipeline of immunotherapy candidates are derived from the company’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Several TRAAC molecules are in various stages of discovery and preclinical development.
Company Details
- Employees
- 19
- Address
- 866 Malcom Rd,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- tallactherapeutics.com
- HQ
- Burlingame
Tallac Therapeutics Questions
Tallac Therapeutics's website is tallactherapeutics.com
Tallac Therapeutics's LinkedIn profile is https://www.linkedin.com/company/tallac-therapeutics
Tallac Therapeutics has
19 employees.
View email and phone details for 19
employees at Tallac Therapeutics.
Tallac Therapeutics's industry is
Biotechnology Research
Tallac Therapeutics's top competitors are
Hinge Bio,
Allogene Therapeutics,
Immune-Onc Therapeutics,
Alx Oncology,
Biotech Ceo Sisterhood,
Olema Oncology,
Akero Therapeutics,
Ascentage Pharma,
Summit Therapeutics, Inc.,
Rain Oncology.
Tallac Therapeutics's categories are Biotechnology Research
